Host-environment interactions in pulmonary fibrosis

Seminars in Respiratory and Critical Care Medicine

Volumn 27, Issue 6, 2006, Pages 574-580

  Garantziotis, Stavros ^a,b   Schwartz, David A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Environmental triggers; Host susceptibility; Idiopathic pulmonary fibrosis

Indexed keywords

ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; CLINICAL FEATURE; CYTOMEGALOVIRUS; DEATH; DISEASE PREDISPOSITION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; FIBROSING ALVEOLITIS; GENETIC SUSCEPTIBILITY; HEPATITIS C VIRUS; HOST; HUMAN; HUMAN HERPESVIRUS 8; INFECTION; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG PARENCHYMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY FAILURE; RISK FACTOR; SMOKING; THEORETICAL STUDY;

DISEASE SUSCEPTIBILITY; DRUG THERAPY; ENVIRONMENTAL EXPOSURE; HUMANS; PROGNOSIS; PULMONARY FIBROSIS; SMOKING; VIRUS DISEASES;

EID: 33845996942     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-957329     Document Type: Article

References (75)

1. Car BD, Meloni F, Luisetti M, Semenzato G, Gialdroni-Grassi G, Walz A. Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med 1994;149(3 Pt 1):655-659
2. Southcott AM, Jones KP, Li D, et al. Interleukin-8: differential expression in lone fibrosing alveolitis and systemic sclerosis. Am J Respir Crit Care Med 1995;151: 1604-1612
3. Tsoutsou PG, Gourgoulianis KI, Petinaki E, et al. Cytokine levels in the sera of patients with idiopathic pulmonary fibrosis. Respir Med; 2006;100:938-945. Epub 2005 Oct 2019
4. Ziegenhagen MW, Zabel P, Zissel G, Schlaak M, Muller-Quernheim J. Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am J Respir Crit Care Med 1998;157(3 Pt 1):762-768
5. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 10 1999;200:1-203
6. Garantziotis S, Steele MP, Schwartz DA. Pulmonary fibrosis: thinking outside of the lung. J Clin Invest 2004; 114:319-321
7. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997;155: 242-248
8. Hubbard R, Lewis S, Richards K, Johnston I, Britton J. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 1996;347:284-289
9. Hubbard R, Cooper M, Antoniak M, et al. Risk of cryptogenic fibrosing alveolitis in metal workers. Lancet 2000;355:466-467
10. Iwai K, Mori T, Yamada N, Yamaguchi M, Hosoda Y. Idiopathic pulmonary fibrosis: epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med 1994; 150:670-675
11. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994;150:967-972
12. Johnston I, Britton J, Kinnear W, Logan R. Rising mortality from cryptogenic fibrosing alveolitis. BMJ 1990;301:1017-1021
13. Selikoff IJ, Hammond EC, Seidman H. Mortality experience of insulation workers in the United States and Canada, 1943-1976. Ann NY Acad Sci 1979;330:91-116
14. Marshall RP, Puddicombe A, Cookson WO, Laurent GJ. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 2000;55:143-146
15. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005;172:1146-1152. Epub 2005 Aug 1118
16. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161(2 Pt 1):646-664
17. Rossi GA, Szapiel S, Ferrans VJ, Crystal RG. Susceptibility to experimental interstitial lung disease is modified by immune- and non-immune-related genes. Am Rev Respir Dis 1987;135:448-455
18. Callis AH, Sohnle PG, Mandel GS, Wiessner J, Mandel NS. Kinetics of inflammatory and fibrotic pulmonary changes in a murine model of silicosis. J Lab Clin Med 1985;105:547-553
19. Reinhard MC, Mirand EA, Goltz HL, Hoffman JG. Mouse-strain differences in response to radiation. Proc Soc Exp Biol Med 1954;85:367-370
20. Schwartz DA, Van Fossen DS, Davis CS, et al. Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994;149(2 Pt 1):444-449
21. Pleis JR, Schiller JS, Benson V. Summary health statistics for U.S. adults: National Health Interview Survey, 2000. Vital Health Stat 10 2003;215:1-132
22. Adams PF, Schoenborn CA, Moss AJ, Warren CW, Kann L. Health-risk behaviors among our nation's youth: United States, 1992. Vital Health Stat 10 1995;192:1-51
23. Glazer CS, Newman LS. Occupational interstitial lung disease. Clin Chest Med 2004;25:467-478
24. Baumgartner KB, Samet JM, Coultas DB, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. Am J Epidemiol 2000;152:307-315
25. Miyake Y, Sasaki S, Yokoyama T, et al. Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. Ann Occup Hyg 2005;49:259-265. Epub 2005 Jan 2007
26. Rimal B, Greenberg AK, Rom WN. Basic pathogenetic mechanisms in silicosis: current understanding. Curr Opin Pulm Med 2005;11:169-173
27. Dai J, Gilks B, Price K, Churg A. Mineral dusts directly induce epithelial and interstitial fibrogenic mediators and matrix components in the airway wall. Am J Respir Crit Care Med 1998;158:1907-1913
28. Hubbs AF, Minhas NS, Jones W, et al. Comparative pulmonary toxicity of 6 abrasive blasting agents. Toxicol Sci 2001;61:135-143
29. Schapira RM, Ghio AJ, Effros RM, et al. Hydroxyl radical production and lung injury in the rat following silica or titanium dioxide instillation in vivo. Am J Respir Cell Mol Biol 1995;12:220-226
30. Tang YW, Johnson JE, Browning PJ, et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol 2003;41: 2633-2640
31. Yonemaru M, Kasuga I, Kusumoto H, et al. Elevation of antibodies to cytomegalovirus and other herpes viruses in pulmonary fibrosis. Eur Respir J 1997;10: 2040-2045
32. Egan JJ, Stewart JP, Hasleton PS, Arrand JR, Carroll KB, Woodcock AA. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax 1995;50:1234-1239
33. Stewart JP, Egan JJ, Ross AJ, et al. The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1999;159 (4 Pt 1):1336-1341
34. Cohen JI. Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases. Semin Hematol 2003;40:116-123
35. Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990;344:777-780
36. Tsukamoto K, Hayakawa H, Sato A, Chida K, Nakamura H, Miura K. Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax 2000;55:958-961
37. Lok SS, Haider Y, Howell D, Stewart JP, Hasleton PS, Egan JJ. Murine gammaherpes virus as a cofactor in the development of pulmonary fibrosis in bleomycin resistant mice. Eur Respir J 2002;20:1228-1232
38. Mora AL, Woods CR, Garcia A, et al. Lung infection with gamma-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice. Am J Physiol Lung Cell Mol Physiol 2005;289:L711-721. Epub 2005 Feb 2025
39. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999;397:710-713
40. Chung MP, Monick MM, Hamzeh NY, Butler NS, Powers LS, Hunninghake GW. Role of repeated lung injury and genetic background in bleomycin-induced fibrosis. Am J Respir Cell Mol Biol 2003;29(3 Pt 1):375-380. Epub 2003 Apr 2003
41. Ueda T, Ohta K, Suzuki N, et al. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis 1992;146:266-268
42. Ferri C, La Civita L, Fazzi P, et al. Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection. Br J Rheumatol 1997;36:360-365
43. Irving WL, Day S, Johnston ID. Idiopathic pulmonary fibrosis and hepatitis C virus infection. Am Rev Respir Dis 1993;148(6 Pt 1):1683-1684
44. Idilman R, Cetinkaya H, Savas I, et al. Bronchoalveolar lavage fluid analysis in individuals with chronic hepatitis C. J Med Virol 2002;66:34-39
45. Yamaguchi S, Kubo K, Fujimoto K, Honda T, Sekiguchi M, Sodeyama T. Analysis of bronchoalveolar lavage fluid in patients with chronic hepatitis C before and after treatment with interferon alpha. Thorax 1997;52:33-37
46. Kuwano K, Nomoto Y, Kunitake R, et al. Detection of adenovirus E1A DNA in pulmonary fibrosis using nested polymerase chain reaction. Eur Respir J 1997;10:1445-1449
47. Hubbard R, Venn A, Smith C, Cooper M, Johnston I, Britton J. Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study. Am J Respir Crit Care Med 1998;157(3 Pt 1):743-747
48. Musk AW, Pollard JA. Pindolol and pulmonary fibrosis. BMJ 1979;2:581-582
49. Erwteman TM, Braat MC, van Aken WG. Interstitial pulmonary fibrosis: a new side effect of practolol. BMJ 1977; 2:297-298
50. Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 1999;36:425-438
51. Patti MG, Tedesco P, Golden J, et al. Idiopathic pulmonary fibrosis: how often is it really idiopathic? J Gastrointest Surg 2005;9:1053-1056; discussion 1056-1058
52. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006;27:136-142
53. Tobin RW, Pope CE II, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;158:1804-1808
54. Brennan NJ, Morris AJ, Green M. Thoracoabdominal mechanics during tidal breathing in normal subjects and in emphysema and fibrosing alveolitis. Thorax 1983;38:62-66
55. Todisco T. Thoracoabdominal mechanics in dyspnea. Respiration 1981;42:77-83
56. Schwartz DJ, Wynne JW, Gibbs CP, Hood CI, Kuck EJ. The pulmonary consequences of aspiration of gastric contents at pH values greater than 2.5. Am Rev Respir Dis 1980;121: 119-126
57. Popper H, Juettner F, Pinter J. The gastric juice aspiration syndrome (Mendelson syndrome): aspects of pathogenesis and treatment in the pig. Virchows Arch A Pathol Anat Histopathol 1986;409:105-117
58. Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006;129:794-800
59. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980;35:171-180
60. Carrington CB, Gaensler EA, Coutu RE, FitzGerald MX, Gupta RG. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298:801-809
61. Crystal RG, Fulmer JD, Roberts WC, Moss ML, Line BR, Reynolds HY. Idiopathic pulmonary fibrosis: clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med 1976;85:769-788
62. Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 2002;41:676-679
63. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581-1586
64. Dong C, Zhu S, Wang T, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002;99:3908-3913
65. Kikuchi K, Kadono T, Ihn H, et al. Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-beta 1. J Invest Dermatol 1995;105:128-132
66. Nicholson AG, Florio R, Hansell DM, et al. Pulmonary involvement by Niemann-Pick disease: a report of six cases. Histopathology 2006;48:596-603
67. Mendelson DS, Wasserstein MP, Desnick RJ, et al. Type B Niemann-Pick disease: findings at chest radiography, thin-section CT, and pulmonary function testing. Radiology 2006; 238:339-345. Epub 2005 Nov 2022
68. Knight S, Vulliamy T, Copplestone A, Gluckman E, Mason P, Dokal I. Dyskeratosis Congenita (DC) Registry: identification of new features of DC. Br J Haematol 1998;103:990-996
69. Lawson WE, Grant SW, Ambrosini V, et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax 2004;59:977-980
70. Lawson WE, Polosukhin W, Stathopoulos GT, et al. Increased and prolonged pulmonary fibrosis in surfactant protein C-deficient mice following intratracheal bleomycin. Am J Pathol 2005;167:1267-1277
71. Thomas AQ, Lane K, Phillips J III, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002;165:1322-1328
72. Liu T, Hu B, Chung MJ, Ullenbruch M, Jin H, Phan SH. Telomerase regulation of myofibroblast differentiation. Am J Respir Cell Mol Biol 2006;34:625-633. Epub 2006 Jan 2019
73. Collins K, Mitchell JR. Telomerase in the human organism. Oncogene 2002;21:564-579
74. Mu XC, Staiano-Coico L, Higgins PJ. Increased transcription and modified growth state-dependent expression of the plasminogen activator inhibitor type-1 gene characterize the senescent phenotype in human diploid fibroblasts. J Cell Physiol 1998;174:90-98
75. Mu XC, Higgins PJ. Differential growth state-dependent regulation of plasminogen activator inhibitor type-1 expression in senescent IMR-90 human diploid fibroblasts. J Cell Physiol 1995;165:647-657